4
Changes in Ownership
Enliven Therapeutics, Inc. Filed Acc 0001415889-25-017730
PRESIDENT AND CEO sold 12,500 shares at an average $22.18 ($277,292)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kintz Samuel PRESIDENT AND CEO | 2025-06-17 | Sale 10b5-1 | −10,502 | $22.08 | $231,839 | 954,890 | I: show line 1 in the form |
| Kintz Samuel PRESIDENT AND CEO | 2025-06-17 | Sale 10b5-1 | −1,998 | $22.75 | $45,453 | 952,892 | I: show line 2 in the form |
| Open-market sales · 12,500 sh · avg $22.18 · $277,292 | |||||||
Loading xslF345X05/form4-06182025_100643.xml…